Circulating tumour DNA (ctDNA) testing is an emerging technology with the potential to transform cancer care, offering minimally invasive insights for detection, diagnosis, and disease monitoring. This IQVIA white paper reviews current evidence and implementation trends in ctDNA testing, outlining its potential across the cancer care continuum and the ongoing technical, regulatory, and reimbursement hurdles that pose barriers to clinical adoption.

Realising the promise of ctDNA testing will require concerted multi-stakeholder collaboration to establish best practice frameworks, share knowledge, and address systemic access barriers. The journey to routine ctDNA testing is ongoing, and its legacy will be a foundation for ever more precise, personalised, and effective cancer care.

Download the white paper now for more insights.